Verve Therapeutics’ co-founder and CEO Sekar Kathiresan offers insight into how he launched a gene editing drug company and dosed the first patient in less than four years.

In an exclusive interview, FDA’s Peter Marks discusses CBER priorities, PDUFA VII funding, and improving the dialogue between regulators and drugmakers.

Each January, the J.P. Morgan healthcare conference helps to set the biopharma industry agenda for the coming year. What will be the next big thing in 2023?

Creativity will be in high demand, not just to control costs during tough economic conditions, but in key functional areas like business development and external collaboration, ESG (environmental, social, and governance), and diversity, equity and inclusion (DE&I).

Our experts talk about everything from alternative financing arrangements to investment trends that biopharma execs should keep their eyes on.

In this Q&A, 10 executives provide their thoughts on what the future holds for biopharmaceutical manufacturing and supply chain operations, and which issues will have the most impact.

Looking through my 2022 coverage areas, and in reading through my colleagues’ outlook articles, what was most compelling to me were not necessarily the specific issues raised, but how leadership approached those issues to create solutions.

The CEO Of Aristea talks about the company’s unusual move to do both a series B round, but not as a crossover, while also making a deal with another pharma company.

Although some of Jack Welch’s past leadership practices have come under fire in recent years, it’s safe to say that one of the most successful CEOs in recent history might have some useful ideas and strategy worth remembering.